You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

advanced HCC

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced HCC, Other Solid Tumors Trial in Shanghai (KD6001, Tislelizumab, Bevacizumab)

Not yet recruiting
  • Advanced HCC
  • Other Solid Tumors
  • Shanghai, China
    Zhongshan Hospital
Jun 13, 2023

Advanced HCC Trial (Lenalidomide)

Not yet recruiting
  • Advanced HCC
  • (no location specified)
Apr 16, 2023

CT Perfusion Parameters for Advanced HCC Treated by Systemic

Completed
  • Advanced HCC Treated by Systemic Immunotherapy
    • Nancy, France
      CHRU Nancy
    Oct 13, 2022

    Hepatocellular Carcinoma Trial (Cryoablation, Tislelizumab, Lenvatinib)

    Not yet recruiting
    • Hepatocellular Carcinoma
    • Cryoablation
    • +2 more
    • (no location specified)
    May 31, 2023

    Hepatocellular Carcinoma, Atezolizumab-bevacizumab, Response Evaluation Trial in Seoul (Early response evaluation)

    Recruiting
    • Hepatocellular Carcinoma
    • +2 more
    • Early response evaluation
    • Seoul, Korea, Republic of
      Seoul National University Hospital
    Feb 28, 2023

    Hepatocellular Carcinoma, Liver Cancer, Adult, Liver Tumor Trial in Duarte (ECT204 T cells)

    Recruiting
    • Hepatocellular Carcinoma
    • +3 more
    • ECT204 T cells
    • Duarte, California
    • +1 more
    Jan 9, 2023

    Hepatocellular Carcinoma Trial (PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE)

    Recruiting
    • Hepatocellular Carcinoma
    • PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
    • TACE
    • Nanjing, China
    • +1 more
    Dec 28, 2022

    Hepatocellular Carcinoma Trial in Guangzhou (Candonilimab, Bevacizumab)

    Withdrawn
    • Hepatocellular Carcinoma
    • Guangzhou, Guangdong, China
      Cancer Center Sun Yat-sen University
    Jun 1, 2023

    Advanced Hepatocellular Carcinoma Trial in Guangzhou (Cadonilimab+regorafenib)

    Active, not recruiting
    • Advanced Hepatocellular Carcinoma
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Mar 6, 2023

    Hepatocellular Carcinoma Trial in Guangzhou (Candonilimab, Bevacizumab)

    Recruiting
    • Hepatocellular Carcinoma
    • Guangzhou, Guangdong, China
      Cancer Center Sun Yat-sen University
    Feb 26, 2023

    Hepatocellular Carcinoma Trial in Guangzhou (HAIC, Zoledronic acid)

    Recruiting
    • Hepatocellular Carcinoma
    • HAIC
    • Zoledronic acid
    • Guangzhou, Guangdong, China
      Cancer Center Sun Yat-sen University
    May 10, 2023

    Hepatocellular Carcinoma Non-resectable Trial in Guangzhou (Sin-Bev-TACE, Len-TACE)

    Recruiting
    • Hepatocellular Carcinoma Non-resectable
    • Guangzhou, Guangdong, China
      the Second Affiliated Hospital of Guangzhou Medical University
    Aug 2, 2023

    Hepatocellular Carcinoma Non-resectable Trial in Guangzhou (TACE combined with lenvatinib and sintilimab)

    Completed
    • Hepatocellular Carcinoma Non-resectable
    • TACE combined with lenvatinib and sintilimab
    • Guangzhou, Guangdong, China
      The Second Affiliated Hospital of Guangzhou Medical University
    Nov 8, 2022

    Hepatocellular Carcinoma Non-resectable Trial in Guangzhou (Lenvatinib plus sintilimab, Lenvatinib)

    Recruiting
    • Hepatocellular Carcinoma Non-resectable
    • Guangzhou, Guangdong, China
      The Second Affiliated Hospital of Guangzhou Medical University
    Nov 2, 2022

    Hepatocellular Carcinoma Trial in Guangzhou (Cadonilimab, transjugular intrahepatic portosystemic shunt (TIPS))

    Not yet recruiting
    • Hepatocellular Carcinoma
    • Cadonilimab
    • transjugular intrahepatic portosystemic shunt (TIPS)
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    May 30, 2023

    Atezolizumab Plus Bevacizumab in Advanced HCC

    Recruiting
    • Advanced Hepatocellular Carcinoma
    • Atezolizumab plus bevacizumab
    • Seongnam-si, Gyeonggi-do, Korea, Republic of
      Cha Medical Center
    Oct 30, 2022

    Locally Advanced Hepatocellular Carcinoma Trial in Singapore (SIRT-Y90 with Atezolizumab + Bevacizumab, SIRT-Y90 with Placebo

    Recruiting
    • Locally Advanced Hepatocellular Carcinoma
    • SIRT-Y90 with Atezolizumab + Bevacizumab
    • SIRT-Y90 with Placebo (IV)
    • Singapore, Singapore
    • +1 more
    Jan 26, 2023

    Hepatocellular Carcinoma Trial in Guangzhou (Donafenib+sintilimab)

    Recruiting
    • Hepatocellular Carcinoma
    • Guangzhou, Guangdong, China
      The Second Affiliated Hospital of Guangzhou Medical University
    Dec 4, 2021

    Advanced Hepatocellular Carcinoma Trial in Hangzhou (Envafolimab, TACE, Lenvatinib)

    Recruiting
    • Advanced Hepatocellular Carcinoma
    • Hangzhou, Zhejiang, China
      the First Affiliated Hospital, School of Medicine, Zhejiang Univ
    Mar 13, 2022

    Hepatocellular Carcinoma Trial in Guangzhou (digital subtraction angiography., FOLFOX (oxaliplatin , leucovorin , fluorouracil ,

    Recruiting
    • Hepatocellular Carcinoma
    • digital subtraction angiography.
    • FOLFOX (oxaliplatin , leucovorin , fluorouracil , and fluorouracil )
    • Guangzhou, Guangdong, China
      Department of Minimally Invasive and Interventional Radiology, L
    Feb 7, 2023

    Advanced Hepatocellular Carcinoma Trial in Guangzhou (drug, procedure, radiation)

    Recruiting
    • Advanced Hepatocellular Carcinoma
    • Guangzhou, Guangdong, China
      The First Affiliated Hospital of Sun Yat-sen University
    Oct 20, 2022

    Hepatocellular Carcinoma Non-resectable Trial in Guangzhou (TACE combined with sorafenib and tislelizumab)

    Completed
    • Hepatocellular Carcinoma Non-resectable
    • TACE combined with sorafenib and tislelizumab
    • Guangzhou, Guangdong, China
    • +1 more
    Oct 11, 2022

    Hepatocellular Carcinoma, Chemo Effect, Chemotherapeutic Toxicity Trial in Guangzhou (Oxaliplatin,calcium folinic acid,

    Recruiting
    • Hepatocellular Carcinoma
    • +2 more
    • Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU
    • +4 more
    • Guangzhou, Guangdong, China
      SUN Yat-sen University Cancer Center
    Sep 11, 2023

    Therapeutic Effects and Clinical Prognosis After HAIC for

    Recruiting
    • Hepatocellular Carcinoma
    • Search of factors predicting therapeutic effects and prognosis
    • Guangzhou, Guangdong, China
      Department of Minimally Invasive and Interventional Radiology, L
    Jun 7, 2022

    HepaSphere Drug-eluting Bead Transarterial Chemoembolization

    Recruiting
    • Advanced Hepatocellular Carcinoma (HCC)
    • DEB-TACE plus HAIC or HAIC alone
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    May 19, 2023